MARKET

LADX

LADX

LadRx
OTCMQB
0.170
0.000
0.00%
Closed 15:52 12/05 EST
OPEN
0.180
PREV CLOSE
0.170
HIGH
0.180
LOW
0.170
VOLUME
23.23K
TURNOVER
4.08K
52 WEEK HIGH
0.860
52 WEEK LOW
0.052
MARKET CAP
7.66M
P/E (TTM)
-0.5250
1D
5D
1M
3M
1Y
5Y
LadRx Corporation Issues Corporate Update for 3Q22
LOS ANGELES, November 17, 2022--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below update to stockholders.
Business Wire · 11/17 14:00
CytRx Corporation Relaunches as LadRx Corporation
LOS ANGELES, September 23, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.
Business Wire · 09/23 13:00
European patent office awards CytRx patent for LADR platform
CytRx Corporation (OTCQB:CYTR) <a href="https://seekingalpha.com/pr/18929754-european-patent-office-awards-cytrx...
Seekingalpha · 09/07 14:26
European Patent Office Awards CytRx Key Patent
LOS ANGELES, September 07, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been awarded a key patent by the Europ...
Business Wire · 09/07 13:00
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
LOS ANGELES, August 09, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (...
Business Wire · 08/09 12:00
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
LOS ANGELES, May 17, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by Ke...
Business Wire · 05/17 12:00
CytRx Partners with Oncology Development Expert to Advance LADR Platform
LOS ANGELES, April 20, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered with oncology development expert...
Business Wire · 04/20 12:00
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress
LOS ANGELES, March 21, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to stockholders.
Business Wire · 03/21 12:00
More
About LADX
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Webull offers kinds of CytRx Corporation stock information, including OTCMQB:LADX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LADX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LADX stock methods without spending real money on the virtual paper trading platform.